Literature DB >> 29506832

Umbilical mesenchymal stromal cells provide intestinal protection through nitric oxide dependent pathways.

Amanda R Jensen1, Natalie A Drucker1, Michael J Ferkowicz1, Troy A Markel2.   

Abstract

BACKGROUND: Umbilical-derived mesenchymal stromal cells (USCs) have shown promise in the protection of ischemic organs. We hypothesized that USCs would improve mesenteric perfusion, preserve intestinal histological architecture, and limit inflammation by nitric oxide-dependent mechanisms following intestinal ischemia/reperfusion (IR) injury.
METHODS: Adult wild-type C57BL/6J (WT) and endothelial nitric oxide synthase knock out (eNOS KO) mice were used: (1) WT IR + vehicle, (2) WT IR + USC, (3) eNOS KO IR + vehicle, and (4) eNOS KO IR + USC. Mice were anesthetized, and a midline laparotomy was performed. The superior mesenteric artery was clamped with a nonoccluding clamp for 60-min. Following IR, mice were treated with an injection of 250 μL phosphate buffered saline or 2 × 106 USCs suspended in 250-μL phosphate buffered saline solution. Mesenteric perfusion images were acquired using laser Doppler imaging. Perfusion was analyzed as a percentage of baseline. At 24 h, mice were euthanized, and intestines were harvested. Intestines were evaluated for injury, and data were analyzed using the Mann-Whitney or Kruskal-Wallis tests.
RESULTS: Intestinal mesenteric perfusion was significantly improved in WT mice treated with USC therapy compared with eNOS KOs. Intestinal histological architecture was preserved with USC therapy in WT mice. However, in eNOS KO mice, this benefit was abolished. Finally, the presence of several cytokines and growth factors were significantly improved in WT mice compared with eNOS KO mice treated with USCs.
CONCLUSIONS: The benefits of USC-mediated therapy following intestinal IR injury likely occur via nitric oxide-dependent pathways. Further studies are required to define the molecular mechanisms by which USCs activate endothelial nitric oxide synthase to bring about their protective effects.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endothelial nitric oxide synthase; Inflammation; Intestine; Ischemia-reperfusion injury; Nitric oxide; Umbilical mesenchymal stromal cells

Mesh:

Substances:

Year:  2017        PMID: 29506832      PMCID: PMC6128694          DOI: 10.1016/j.jss.2017.11.068

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  28 in total

Review 1.  Intestinal (mesenteric) vasculopathy. I. Acute superior mesenteric arteriopathy and venopathy.

Authors:  M S Cappell
Journal:  Gastroenterol Clin North Am       Date:  1998-12       Impact factor: 3.806

Review 2.  Allogeneic and xenogeneic transplantation of adipose-derived stem cells in immunocompetent recipients without immunosuppressants.

Authors:  Ching-Shwun Lin; Guiting Lin; Tom F Lue
Journal:  Stem Cells Dev       Date:  2012-07-03       Impact factor: 3.272

Review 3.  Mesenteric Ischemia.

Authors:  Daniel G Clair; Jocelyn M Beach
Journal:  N Engl J Med       Date:  2016-03-10       Impact factor: 91.245

Review 4.  Paracrine Mechanisms of Mesenchymal Stem Cells in Tissue Repair.

Authors:  Massimiliano Gnecchi; Patrizia Danieli; Giuseppe Malpasso; Maria Chiara Ciuffreda
Journal:  Methods Mol Biol       Date:  2016

5.  Role of interleukin-10 in the pathogenesis of necrotizing enterocolitis.

Authors:  Claudia N Emami; Nikunj Chokshi; Jin Wang; Catherine Hunter; Yigit Guner; Kerstin Goth; Larry Wang; Anatoly Grishin; Henri R Ford
Journal:  Am J Surg       Date:  2012-04       Impact factor: 2.565

6.  Secretomes from bone marrow-derived mesenchymal stromal cells enhance periodontal tissue regeneration.

Authors:  Takamasa Kawai; Wataru Katagiri; Masashi Osugi; Yukiko Sugimura; Hideharu Hibi; Minoru Ueda
Journal:  Cytotherapy       Date:  2015-01-14       Impact factor: 5.414

7.  Harvest tissue source does not alter the protective power of stromal cell therapy after intestinal ischemia and reperfusion injury.

Authors:  Amanda R Jensen; Morenci M Manning; Sina Khaneki; Natalie A Drucker; Troy A Markel
Journal:  J Surg Res       Date:  2016-05-11       Impact factor: 2.192

8.  Human Adipose Stromal Cells Increase Survival and Mesenteric Perfusion Following Intestinal Ischemia and Reperfusion Injury.

Authors:  Amanda R Jensen; Dominique L Doster; E Bailey Hunsberger; Morenci M Manning; Samantha M Stokes; Daria Barwinska; Keith L March; Mervin C Yoder; Troy A Markel
Journal:  Shock       Date:  2016-07       Impact factor: 3.454

9.  The age-adjusted Charlson Comorbidity Index as an outcome predictor of patients with acute mesenteric ischemia.

Authors:  Joaquin Marchena-Gomez; Maria Asuncion Acosta-Merida; Marion Hemmersbach-Miller; Alicia Conde-Martel; Cristina Roque-Castellano; Juan Hernandez-Romero
Journal:  Ann Vasc Surg       Date:  2009-01-06       Impact factor: 1.466

Review 10.  Stem cells as a potential future treatment of pediatric intestinal disorders.

Authors:  Troy A Markel; Paul R Crisostomo; Tim Lahm; Nathan M Novotny; Frederick J Rescorla; Joseph Tector; Daniel R Meldrum
Journal:  J Pediatr Surg       Date:  2008-11       Impact factor: 2.545

View more
  3 in total

1.  Inhibiting hydrogen sulfide production in umbilical stem cells reduces their protective effects during experimental necrotizing enterocolitis.

Authors:  Natalie A Drucker; Jan P Te Winkel; W Christopher Shelley; Kenneth R Olson; Troy A Markel
Journal:  J Pediatr Surg       Date:  2019-03-01       Impact factor: 2.545

Review 2.  Mesenchymal stem cells against intestinal ischemia-reperfusion injury: a systematic review and meta-analysis of preclinical studies.

Authors:  Yajing Shi; Xiaolan Zhang; Zhanhai Wan; Xin Liu; Feng Chen; Jianmin Zhang; Yufang Leng
Journal:  Stem Cell Res Ther       Date:  2022-05-26       Impact factor: 8.079

Review 3.  Stem cell therapy as a promising strategy in necrotizing enterocolitis.

Authors:  Si-Jia Di; Si-Yuan Wu; Tian-Jing Liu; Yong-Yan Shi
Journal:  Mol Med       Date:  2022-09-06       Impact factor: 6.376

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.